Vimarsana
Biggest News Aggregation in the World

Page 18 - T Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from T Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In T Cell Today - Breaking & Trending Today

Unlocking the power of mRNA vaccines: From COVID-19 to cancer and beyond - Vimarsana News

Unlocking the power of mRNA vaccines: From COVID-19 to cancer and beyond

A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.

CD1 lipidomes exhibit size-based antigen display mechanisms - Vimarsana News

CD1 lipidomes exhibit size-based antigen display mechanisms

Study uncovers the complexities of how CD1 molecules present a vast array of lipids to T-cells, revealing a unique, size-based antigen-display system. The findings could provide crucial insights into the intricacies of immune response and antigen presentation.

Patients With Rheumatism Have Premature Immune System Aging - Vimarsana News

Patients With Rheumatism Have Premature Immune System Aging

Researchers have studied how the T-cell aging process translates into metabolic reprogramming of the T-cells in patients with rheumatoid arthritis.

U of A alum wins major award for cancer-fighting immunotherapy discovery - Vimarsana News

U of A alum wins major award for cancer-fighting immunotherapy discovery

Michel Sadelain is being awarded the Breakthrough Award in Life Sciences for his discovery of CAR T cells, which uses cells to heal cancer patients.

Source: cisnfm.com
Subclonal neoantigens a key roadblock in MMRd tumor immunotherapy success - Vimarsana News

Subclonal neoantigens a key roadblock in MMRd tumor immunotherapy success

Researchers evaluated sensitivity to immune checkpoint blockade (ICB) therapy.